Navigation Links
Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Date:10/15/2007

AMSTERDAM, October 15 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that it has acquired the rights to the discovery of a major mechanism of resistance to the frequently-used breast cancer drug Herceptin(R), which is published in the October 15 issue of the journal "Cancer Cell".

The antibody drug Herceptin(R) targets the HER2 protein, which is hyper-active in about one in four breast cancers and the HER2 protein contributes to aggressive cancer behavior. Striking initial responses are observed in combination with chemotherapy in more than half of treated patients. However, the majority of responding patients eventually develop resistance to Herceptin-based therapies. The laboratory of Agendia's Chief Scientific Officer, Prof. Rene Bernards, today published a rapid method to identify biomarkers associated with non-responsiveness to cancer drugs in cell culture and used the technology to identify a mechanism of resistance to Herceptin-based cancer therapy. His work also demonstrated that these biomarkers indeed have predictive value in patients treated with this drug, thus validating the approach.

"The availability of biomarkers that predict responses to cancer therapy is instrumental to the rational use of cancer drugs in the clinic. Elucidating the molecular mechanism of drug resistance can be critical to identify patients that fail to respond to therapy and may help design more efficient treatment protocols", says Rene Bernards. "Although more work is needed to further validate our findings, the method is generally applicable to find mechanisms of drug resistance and should expedite the development of biomarkers that are associated with therapy non-responsiveness".

The technology used relies on the simultaneous inactivation of thousands of genes through a process known as RNA interference in cells that are sensitive to a specific cancer drug. If the inactivation of a specif
'/>"/>

SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mass. , May 23, 2013 Pressure ... announced that the Company will host a teleconference to ... provide a business update. The teleconference information is provided ... 11:00 a.m. Eastern Daylight Time (EDT) Dial-in: ... ); (302) 607-2001 (Int,l) Passcode: VS22823 For ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Bed bugs already ... the pests is still ongoing, a report from kmov.com suggested ... for the bed bug treatment. Meanwhile, to be of help, ... from the costly bed bug exterminator service. , ... that AHA has so far spent $35,000 for ...
(Date:5/23/2013)... Newmarket, NH (PRWEB) May 23, 2013 Ralph ... all of their emergency management products and emergency survival ... , This announcement was made at the quarterly executive ... meeting with a moment of silence for the Oklahoma tornado ... executives that the quality of their emergency kits is paramount. ...
Breaking Biology Technology:Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2
... Markets ... New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction ... -, ... "the Company"), a pharmaceutical,company dedicated to improving health through the development, manufacture,and commercialization of a ...
... Hearing -, MONTVALE, N.J., June 9 Memory ... June 6, 2008 it received a,letter from the NASDAQ ... not regained compliance with the $1.00 bid,price requirement set ... delisting from The NASDAQ Global Market, unless the Company,requests ...
... and LONDON, June 9 Paul Capital Healthcare,today ... moderate,a panel on strategic biotechnology financing at the ... participants with,how to use revenue streams as a ... Structured Revenue Financing as a Strategy for Meeting,Biotechnology,s ...
Cached Biology Technology:American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 2Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 3Paul Capital Healthcare Leads Panel on Strategic Financing 2
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... A new, streamlined approach to genetic engineering drastically ... new genes into bacteria, the workhorses of biotechnology, ... ACS Synthetic Biology , the method paves the ... for drug development, environmental cleanup and other activities. ... or integrating, a piece of the genetic material ...
(Date:5/22/2013)... Irvine, Calif., May 22, 2013 Early screening for ... personal pregnancy testing is for women, thanks to UC ... the American Chemical Society . , After more than ... a way to clearly identify clinically usable markers for ... be detected far sooner, with greater accuracy and at ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... molecular biophysics and biochemistry at Yale has received a ... on the delivery of a targeted therapy for prostate cancer ... Hu have developed a way to directly target and destroy ... while leaving normal tissue unharmed. , The technology ...
... short-term treatment with a drug compound substantially improved learning ... researchers at the Stanford University School of Medicine and ... for months after the treatment was discontinued. The researchers ... the compound has a similar effect in humans with ...
... rich in black soya beans could help control weight, lower ... diabetes, reports Lisa Richards in Chemistry & Industry, the magazine ... for its cholesterol lowering capabilities; this is one of the ... beans to its range. However, a team of Korean researchers ...
Cached Biology News:Nanoparticles for delivery of prostate cancer treatment 2Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 2Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 3Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 4
...
... and flexibility of the BDTM LSR, the first UV ... The BD LSR II has performance, capabilities, and ... Free up your high-performance cell sorter by moving your ... LSR II. The BD LSR II can be configured ...
... is used to screen blots of mini format ... screen up to 40 different antibodies or sera ... The apparatus includes a base plate, 2 separate, ... 8 x 7 cm membranes, and gaskets and ...
...
Biology Products: